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Abstract
Maintenance with a triple nucleoside reverse transcriptase Inhibitor (NRTI) regimen after successful induction
with a dual NRTI/protease inhibitor (PI) combination may be advantageous, because of low pill burden,
favorable lipids, and less drug interactions. This strategy to become free of PI-related problems without losing
viral efficacy has not been formally tested. We performed a randomized, open-label, multicenter, 96-week
comparative study in antiretroviral therapy (ART)-naı¨ve patients with CD4 350 cells/mm3 and HIV-1 RNA
concentrations (viral load [VL]) greater than 30,000 copies per milliliter. Patients were randomized after reaching
VL less than 50 copies per milliliter on two consecutive occasions between 12 and 24 weeks after start of
zidovudine/lamuvidine and lopinavir/ritonavir combination. Eligible subjects switched to abacavir/lamivudine/
zidovudine (TZV) or continued the PI-containing regimen. Here we present the 48-week data with virologic
success rate (failure: VL> 50 copies per milliliter). Two hundred seven patients had similar baseline (BL) char-
acteristics: median CD4 180 cells/mm3, median VL 5.19 log10 copies per milliliter. One hundred twenty subjects
(58%) met randomization criteria. Baseline VL differed significantly between dropouts and randomized subjects
(median 5.41 versus 5.06 log10 copies per milliliter, p¼ 0.017), as did CD4 cells (median 160 and 200 cells/mm3,
p¼ 0.044). Sixty-one subjects received TZV and 59 subjects continued NRTIs/PI. At week 48, 2 patients in the TZV
group and 5 in the PI group did not have a sustained virologic suppression (log rank test; p¼ 0.379). CD4 counts
increased significantly in both arms. In ART-naı¨ve patients, TZV maintenance had similar antiviral efficacy
compared to continued standard ART at 48 weeks after baseline. Patients on successful standard ART can be safely
switched to a NRTI-only regimen, at least for the tested time period.
Introduction
Current standard therapy of HIV infection consists ofa two-class combination of three antiretroviral (ART)
agents1 (Panel on Antiretroviral Guidelines for Adult and
Adolescents. Guidelines for the use of antiretroviral agents in
HIV-1-infected adults and adolescents. Department of Health
and Human Services. December 1, 2009. www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf ). Preferred
starting regimens include a backbone of two nucleoside
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reverse transcriptase inhibitors (NRTIs) either combined with
a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a
ritonavir-boosted protease inhibitor (PI). In the backbone, one
of two NRTIs may be a nucleotide reverse transcriptase in-
hibitor (NtRTI). These combination antiretroviral therapies
(cART) usually suppress HIV replication adequately, with
increase of CD4 cell count and at least partial restoration
of immunity. Triple-NRTI regimens are generally not re-
commended, although in ART-naı¨ve patients, the combination
of abacavir/lamivudine/zidovudine (TZV) demonstrated vi-
rologic activity comparable to indinavir-based,1,2 nelfinavir-
based,3 and atazanavir-based4 regimens. In two of these
studies1,4 virologic response to TZVwas suboptimal in subjects
with higher baseline viral loads (HIV1-RNA 100,000 copies
per milliliter). In addition, the AIDS Clinical Trial Group
(ACTG) 5095 study showed that TZV was inferior to an efa-
virenz (EFV)-based regimen regardless of baseline viral load.5
Current cART has been associated with significant short-
and long-term adverse events, including hyperlipidemia,
insulin resistance, and lipodystrophy syndrome.6–8 These
metabolic side effects appear to translate into an increase of
cardiovascular events in HIV-infected patients compared to
HIV-seronegative individuals.8–11 Because of these and other
toxicities, there is a need to explore other therapeutic ap-
proaches, including induction-maintenance strategies with
simplified treatment regimens.
Simplifying treatment regimens can also improve adher-
ence, which in turn is pivotal to achieve optimal response to
treatment.12 Complex regimens, higher daily pill burden, and
higher dosing frequencies are predictors of nonadherence,
with relatively low difference between once or twice daily
dosing.13–15 PI-based regimens appear associated with lower
adherence compared to triple NRTI regimens.16–18 Lower
adherence to PI-based cART than to NNRTI-based regimens
has also been shown.19,20 Similar adherence was observed
during maintenance phase between patients on a NRTI-only
regimen or a NNRTI-based regimen.21 Compared to contin-
ued quadruple NNRTI-based treatment, adherence to triple
NRTI maintenance therapy was better.22
Earlier studies addressing a switch to triple NRTI included
patients who had not been ART-naı¨ve from the start, resulting
in suboptimal responses.17,21,23–27 Subsequent studies explor-
ing the induction–maintenance concept in ART-naı¨ve patients
showed similar virologic success (i.e., noninferiority) for triple
NRTI regimens compared to two-class cART.16,21,22,28–31
However, some of these studies were not entirely prospec-
tive,16,21,29 or did not have a comparative design for the
maintenance phase,28,30 or used poorly tolerated quadruple
regimens as induction regimens.22,32
Here we describe a randomized, prospective study in ART-
naı¨ve patients using a standard triple cART as induction
therapy, followed by maintenance with TZV in those who
reached an undetectable plasma viral load (less than 50 copies
per milliliter). We report the interim results at 48 weeks after
baseline, specifically addressing the question of virologic
efficacy of maintenance with single-class ART.
Methods
Study population
HIV-1–infected, ART-naı¨ve adults were eligible with a CD4
cell count 350 cells/mm3 and an HIV-1 RNA level 30,000
copies per milliliter or more at screening. Exclusion criteria
included diabetes mellitus or being treated for abnormality of
the lipid spectrum. Laboratory exclusion criteria were hemo-
globin< 10g/dL (male) or 9 g/dL (female), absolute neutrophil
count< 1000 cells/mm3, platelet count< 75,000 cells/mm3,
transaminases more than 5 times the upper limit of normal
(ULN), total bilirubin> 2mg/L, serum pancreatic amylase
more than 1.5 times the ULN, fasting glucose> 6.9mmol/L
or nonfasting glucose> 11mmol/L, fasting triglyceride
level> 4mmol/L, or fasting LDL cholesterol> 5mmol/L or
low-density lipoprotein/high-density lipoprotein (LDL/HDL)
ratio> 5. Patients were also excluded if they had a history of
cardiovascular events or diabetes mellitus, combined with
fasting triglyceride level> 3mmol/L, or fasting LDL choles-
terol> 4mmol/L, or LDL/HDL ratio> 4.
Study design and study sites
FREE is an investigator-initiated, randomized, open-label,
96-week study conducted at 10 sites in the Netherlands and 1
site in Belgium. During the induction phase, all patients were
treated with 1 fixed-dose tablet of lamivudine (3TC) 150mg/
zidovudine (ZDV) 300mg (Combivir; GlaxoSmtihKline,
Zeist, The Netherlands, and Genval, Belgium) twice daily and
with 3 capsules lopinavir (LPV) 133mg/ritonavir (r) 33mg
(Kaletra; Abott, Hoofddorp, The Netherlands and Louvain-
La-Neuve, Belgium) twice daily. In 2005, the manufacturer
changed the formulation of LPV/r, and the capsules were
replaced by tablets200/50mg, 2 tablets taken twice daily.
Only patients with HIV-1 RNA levels less than 50 copies
per milliliter between week 12 and week 24, measured on two
consecutive visits at least 4 weeks apart, were eligible for
randomization into the maintenance phase. Patients were
randomized on a 1:1 basis by computer-generated allocation
to either continue 3TC/ZDV and LPV/r (PI arm) or to 1 fixed-
dose tablet of Abacavir 300mg/3TC 150mg/ZDV 300mg
(Trizivir; GlaxoSmtihKline, Zeist, The Netherlands, and
Louvain-La-Neuve, Belgium; the TZV arm), twice daily. A
minimization rule was applied for the patient factor: HIV-1
RNA copy number. Patients were stratified in three groups:
30,000–100,000; more than 100,000– 1,000,000; or more than
1,000,000 copies per milliliter at study entry. Screening eval-
uation included a clinical assessment and laboratory evalua-
tions: plasma HIV-1 RNA, CD4 cell count, hematology,
clinical chemistries, and collections of a plasma sample for
retrospective research for viral resistance mutations. Screen-
ing for the presence of the human leukocyte antigen
(HLA)-B*5701 subtype was not performed. In recent years a
statistically significant correlation with the abacavir hyper-
sensitivity reaction and the presence of this allele has been
shown.33 At the time this study was started routine geno-
typing for the HLA-B*5701 allele was not available. On-study
evaluations included clinic visits at baseline and at week 4, 8,
12, 18, and 24, for the induction phase; and at weeks 36, 48, 60,
72, 84, and 96 for the maintenance phase. HIV-1 RNA was
assessed locally at each visit using the Roche Ultrasensitive
Assay (Roche Diagnostics, Indianapolis, IN) with a lower
limit of detection of less than 50 copies per milliliter.
End points
The primary end point of the study was antiviral efficacy at
week 96, defined as plasma HIV-1 RNA less than 400 copies
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per milliliter. The purpose of the study was to assess treatment
equivalence of this endpoint between both groups. Secondary
end points included safety and tolerability; effect on absolute
and cumulativeCD4þ cell count changes compared to baseline;
use of cART related comedication, especially lipid-lowering
agents; and time to treatment failure (HIV-1 RNA less than
50 copies per milliliter). Here we addressed the secondary end
points at week 48: virologic efficacy (sustained viral load
suppression less than 50 copies per milliliter), and premature
discontinuation of allocated ART for any reason. We consid-
ered detectable viral load as well as treatment discontinuation
as treatment failure for the present interim analysis.
Sample size
With an expected antiviral efficacy percentage of 80% at
week 96 and an equivalence limit of 20 percent points (as
assumed in the protocol), 50 randomized evaluable subjects
per group are needed to show equivalence with 80% power,
using a test size of 0.05 (one-sided).
Statistical analyses
Time to virologic failure was analyzed using the Kaplan-
Meier method, and the log-rank test was used to compare
survivor functions (sustaining HIV-RNA less than 50 copies
per milliliter) between groups. The 95% confidence interval
was estimated for the difference in the percentages of treat-
ment failure (virologic failure or premature discontinuation)
between the two groups. All tests for secondary end points
were two-sidedwith a confidence level of 95%. Changes in the
absolute numbers of CD4 cells during the randomization
phase were analyzed using mixed-model analysis of variance
(ANOVA). Statistical analyses were performed using SPSS
version 16 (SPSS, Inc., Chicago, IL).
Ethics
The protocol was approved by Institutional Review Boards
of all hospitals involved. All participants gave consent after
written information had been given, in accordance with the
national and international legislation, as well as the Declara-
tion of Helsinki.
Role of sponsor
This was an investigator-driven study; the sponsor was not
involved in the design, data analysis, draft of the paper, or in
the decision to submit the paper for publication.
The protocol (with revisions and updates) was regis-




Of 241 patients screened, 207were enrolled in the induction
phase. Table 1 shows their demographic and baseline char-
acteristics. Patients at baseline were predominantly male,
with a median age of 40.8 years (range, 19.4–78.1), had a
median baseline HIV-1 RNA 5.19 log10 copies per milliliter
(range, 2.97–7.45), and a median CD4 cell count 180/mm3
(range, 10–440). Eighty-seven patients (36%) did not reach the
maintenance phase (Fig. 1) primarily because they did not
achieve virologic suppression (HIV-1 RNA less than 50 copies
per milliliter on two occasions) before week 24 (47 patients,
54%), or because of side effects (22 patients, 25%). Of baseline
variables only HIV-1 RNA level and CD4 cells differed sig-
nificantly between the patients who did not reach the main-
tenance phase of the study (drop outs; HIV-1 RNA median
5.41 log10 copies per milliliter) and the patients who could be
randomized (median 5.06 log10 copies per milliliter). Median
CD4 cell count was 160 cells/mm3 in the dropouts and
200 cells/mm3 in the randomized group. A total of 120 pa-
tientswere randomized to either continuation of the induction
regimen (n¼ 59) or to switch to TZV (n¼ 61). The two groups
were similar, and characteristics did not change between
initial enrolment of participants and at randomization
(Table 1). Nine patients were randomized, but did not start
with the maintenance phase, 5 patients randomized into the
PI arm, and 4 into the TZV arm. These 9 patients had no
follow-up visits during the maintenance phase and were ex-
cluded from the analyses. Figure 1 provides details about
these study participants that did not follow the allocated
treatment regimen.
Table 1. Demographic and Baseline Characteristics of Patients
Induction phase Maintenance phase
CBV/LPV/r CBV/LPV/r TZV
(n¼ 207) (n¼ 59) (n¼ 61)
Median age (range), yr 39.7 (19.4–78.1) 40.3 (24.7–62.0) 43.1 (21.9–68.6)
Male sex, n (%) 181 (87%) 52 (88%) 50 (82%)
Median baseline plasma HIV-1 RNA
Level (range), log10 copies/mL 5.19 (2.97–7.45) 5.03 (4.17–6.61) 5.07 (2.97–6.18)
100,000 copies/mL 115 (60%) 29 (49%) 33 (54%)
Median CD4 cell count at baseline
cells/mm3 (range) 180 (10–440) 207 (10–370) 195 (10–437)
<50 cells/mm3, n (%) 31 (15%) 6 (11%) 9 (16%)
>50-<200 cells/mm3, n (%) 73 (35%) 18 (34%) 20 (35%)
Median CD4 cell count at randomization
cells/mm3 (range)
NA 350 (50–610) 310 (50–780)
NA, not applicable.
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Virologic response and treatment (dis-)continuation
At week 48, the proportion of patients with treatment fail-
ure (virologic or treatment discontinuation) was 12% (7/57) in
the TZV group and 11% (6/54) in the PI group. The difference
between the TZV group and the PI group was 1.2 percentage
points (TZV-PI; 95%CI –11.0 toþ 13.4). With these confidence
limits lying wholly in the predefined range equivalence is
demonstrated. In the TZV group most failures (5/7) were not
virologic but premature discontinuations because of adverse
events. Five patients in the PI group hadHIV-1 RNA 50 copies
permilliliter ormore at any one time before the endofweek 48,
compared to two patients in the TZV group (log rank test;
p¼ 0.379). In twoof thepatients in thePI grouponly a transient
viral ‘‘blip’’ (defined as a single isolated or recurrent but
transient episode of detectable low-level viremia greater than
50 copies per milliliter) was detected (at week 24 and at week
36), the three other patients had HIV-RNA greater than 50
copies permilliliter for the first time at their visit inweek 48. In
the TZV group one patient had HIV-1 RNA greater than 50
copies per milliliter in week 36, with no result known at week
48. The second patient in the TZV group had HIV-1 RNA
greater than 50 copies per milliliter only at week 48.
There was an increase of CD4 cells in both maintenance
treatment arms at week 48 compared to their CD4 cell counts
at randomization: in the PI group 95 (95% CI 42–149) CD4
cells/mm3 ( p¼ 0.001), and in the TZV group 69 (95% CI 25-
113) CD4 cells/mm3 ( p¼ 0.002). The increase of CD4 cells at
week 48 was not significantly different between groups
( p¼ 0.46).
Discussion
The FREE trial is the first study exploring a 100% pro-
spective, well-designed induction-maintenance strategy in
ART-naı¨ve patients after induction therapy with standard
cART.We show that viral suppression can bemaintained by a
single-class regimen after successful induction by two-class
triple cART standard induction therapy. At week 48, virologic
success rates with the triple NRTI regimen (TZV: 96.5%) and
the continued standard PI-based cART regimen (90.7%) were
similar.
Our interim results confirm findings from two earlier
studies showing that the induction-maintenance approach is
effective,22,32 but induction therapy in these studies consisted
of four drugs, TZV, and EFV. In these studies the four-drug
regimens had high discontinuation rates (24% and 37%). The
Trizefal study30 compared two quadruple induction regi-
mens, TZV with either LPV/r or EFV, which after successful
induction were followed by maintenance therapy with TZV.
In the induction phase there was also a high discontinuation
rate: 45% did not reach the maintenance phase primarily be-
cause of adverse events. Althoughwe show that a triple cART
as induction therapy can be followed successfully by a single-
class maintenance regimen, our dropout was fairly high,
mainly because of strict inclusion criteria for the decision to
FIG. 1. Flow chart and disposition of study
participants in the FREE trial; interim results
at week 48.
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switch to maintenance. Undetectable viral load (HIV-1
RNA< 50 copies per milliliter) on two different visits 4–6
weeks apart within 24 weeks after baseline was an unattain-
able goal for nearly half the patients; only 58% of patients
enrolled at baseline could therefore be randomized. Patients
(42%) who could not be randomized had significantly higher
HIV-1 RNA copies per milliliter, and a lower CD4 count at
baseline. Other studies used longer induction periods (24–48
weeks)22,30 and such policy would have increased the sample
size of our study subjects. The rationale to determine a rela-
tively short induction period was the fear to include subjects
with pre-existing resistant mutant (quasi-)species virus with
an enhanced chance to fail on a single class NRTImaintenance
regimen. Since the average second phase HIV-1 RNA decay
after cART initiation is 2–4 weeks on average,34 treatment of
approximately 6–12 half-lives, or approximately 24–48weeks,
would result in a substantially reduced residual viral burden
at the time of treatment simplification. Our findings at
48 weeks suggest that such a policy to prolong the induction
phase to reduce the risk for failure may not be necessary for
those subjects that reach undetectable viral loads at week 20
and week 24, as virologic failure was equally uncommon in
both arms of our study analyzed at week 48.
Potential weaknesses of our study are first, the limited
sample size; had the design allowed for randomization with
viral suppression after week 24, this would have increased the
sample size. Second, lack of concealmentmay have influenced
failure rates, especially because the major source of failure
was not virologic failure per se, but rather stopping study
medication ‘‘for any reason.’’ Third, at this interim analysis at
week 48, it is too early to predict the success of simplified
treatment with TZV if such maintenance regimen were con-
tinued for longer periods of time.
The simplification of cART after a successful induction
period to a single-class regimenmay be advantageous, even if
such simplified treatment were only justified for limited pe-
riods of time. Triple NRTI regimens offer convenient dosing
regimens with a very low pill burden (two pills per day)
leading to better adherence, show favourable lipid pro-
files,16,22,25 and result in fewer potentially serious drug in-
teractions than standard cART. This may be helpful if during
intercurrent medical or surgical events, drug–drug interac-
tions need to be avoided, e.g., the use of rifamycin-based
regimens for tuberculosis and non tuberculous mycobacterial
infections; anti-convulsive, anti-arrhythmic, or antimalaria
therapy. Based on our observations, patients with viral sup-
pression who need to interrupt PI or NNRTI agents, can be
safelymanagedwith single class NRTI—at least temporarily—
with acceptably low chances of viral failure. With continued
viral suppression less than 50 copies per milliliter, the chances
of acquiring drug resistance are generally low.35
Although there was a low virologic failure rate after ran-
domization in both arms in our study at week 48, results at
week 96 have to be awaited to determine the safety and effi-
cacy of single-class NRTI maintenance therapy during longer
periods of time.
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